Gilead Says Trodelvy Improved Quality of Life in Breast Cancer in Study

By Michael Dabaie

Gilead Sciences Inc. said new data showed its treatment Trodelvy significantly improved quality of life over the standard of care in 2L+ metastatic triple-negative breast cancer.

The company said that in addition to previously reported overall survival benefit observed with Trodelvy compared with chemotherapy, this new subanalysis demonstrated significant and clinically meaningful improvements in health-related quality of life.

Gilead said it presented the results at the European Society of Medical Oncology Congress 2021. TNBC is the most aggressive type of breast cancer and accounts for about 15% of all breast cancers, Gilead said.

"In TNBC, limited treatment options and poor survival outcomes are compounded by a significant decrease in quality of life, especially in relapsed or refractory metastatic disease, where patients can undergo many rounds of chemotherapy," said Sibylle Loibl of the Center for Hematology and Oncology at Bethanien-Hospital Frankfurt. "Trodelvy is not only the first treatment to extend survival in these patients, but this analysis shows it can also significantly lessen the burden of symptoms when quality time is especially important," she said.

Gilead also said new data from the Phase 3 Ascent study in metastatic TNBC showed Trodelvy improved progression-free survival, overall survival and objective response rate compared with chemotherapy in patients who weren't initially diagnosed with TNBC.

"In the metastatic stage of breast cancer, it is not uncommon for people to change from one subtype to another," said Javier Cortes, head of the International Breast Cancer Center in Madrid and Barcelona.

Roughly one-third of patients with TNBC in the study weren't originally diagnosed with TNBC, and still experienced a survival benefit with Trodelvy compared with chemotherapy, Gilead said.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

September 16, 2021 08:20 ET (12:20 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.